CN102198191B - Quick acting medicine for treating prostate and urinary system infections, and production process thereof - Google Patents
Quick acting medicine for treating prostate and urinary system infections, and production process thereof Download PDFInfo
- Publication number
- CN102198191B CN102198191B CN 201110132678 CN201110132678A CN102198191B CN 102198191 B CN102198191 B CN 102198191B CN 201110132678 CN201110132678 CN 201110132678 CN 201110132678 A CN201110132678 A CN 201110132678A CN 102198191 B CN102198191 B CN 102198191B
- Authority
- CN
- China
- Prior art keywords
- medicine
- powder
- treatment
- weight
- urinary system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a quick acting medicine for treating prostate and urinary system infections, and a production process thereof. The quick acting medicine can quickly and effectively treat prostate and urinary system infections without toxic side effects, is convenient to take, can eliminate the root cause of illness, and has easy availability of raw materials and high cure rate. The medicine contains the following raw materials in percentage by weight: 25-30% of clerodendrum bungei extract and 70-75% of perilla leaf extract, and the sum of the percentages by weight of the raw materials is 100%. The production process of the medicine comprises the steps of: respectively cleaning the clerodendrum bungei and the perilla leaf up, pulverizing by a pulverizer into powder of 80-120 meshes; adding water 1-10 times of the weight of the powder, heating in a heating cylinder for 15-30 minutes until the boiling point is 80-100 DEG C; sucking into a high-speed centrifuge and centrifuging for 15 minutes to automatically separate the dregs of decoction, sucking the liquid medicine into a spray drying tower to obtain dry powder; and packing in aluminum foil bags, putting 25-30% of clerodendrum bungei powder and 70-75% of perilla leaf powder into a sealed stirrer and stirring for 15 minutes, sterilizing, and packing into capsules or tablets to obtain the finished product of the medicine.
Description
Technical field
The present invention relates to a kind of medicine and production technology thereof, relate in particular to quick-acting medicines and the production technology thereof for the treatment of prostate and urinary system infection.
Background technology
World Health Organization (WHO) in 2009 announces that prostate and diseases of urinary system have become one of primary disease of destroying men's health, and add up according to World Health Organization (WHO): the whole world has nearly male more than 40% to suffer from for a long time prostate and the infection diseases of urinary system of different symptoms throughout the year.Various countries are in for prostate and infection diseases of urinary system treatment at present, great majority adopt each antibiotics and antibiotic medicine, but this type of medicine generally can only take stopgap measures and not effect a permanent cure this disease, and antibiotic Reusability can cause the destruction of body immunity and goes down; Having a kind of is exactly to adopt excision prostatic hyperplasia shape again, yet operation can damage the neural and all bands of gland of the contraction of body of gland to a great extent, and also will recur after a period of time.
Summary of the invention
The objective of the invention is to be improved, innovate for the shortcoming that exists in the present background technology and problem, a kind of quick-acting medicines and production technology thereof for the treatment of prostate and urinary system infection is provided.
In order to solve the existing problem of background technology, the present invention is by the following technical solutions: the raw material components that contains following percentage by weight in the medicine of the present invention: Caulis et folium clerodendri bungei extracted dry powder 25%-30%, Folium Perillae extracted dry powder 70%-75%.Above raw material components percentage by weight sum is 100%.
Production technology embodiment of the present invention is:
A kind of production technology for the treatment of prostate and the quick-acting medicines of urinary system infection, it is characterized in that the component raw material of following proportioning is mixed, stir, sterilize with sealed blender, pack etc. with capsule or tablet and to get final product: raw material components Caulis et folium clerodendri bungei extracted dry powder 25%-30%, Folium Perillae extracted dry powder 70%-75%.Above raw material components percentage by weight sum is 100%.
1, with the Caulis et folium clerodendri bungei clean it up, be ground into 80-120 order powder through pulverizer, heated 15-30 minute in the heating cylinder with powder weight 1-10 water doubly, 80 degrees centigrade to 100 degrees centigrade of boiling points, suction high speed centrifuge 15 minutes, automatically after isolating medicinal residues, medicinal liquid suction spraying drying tower is namely got the powdered thing, pack with thin aluminum bag.
2, with the Folium Perillae clean it up, be ground into 80-120 order powder through pulverizer, heated 15-30 minute in the heating cylinder with powder weight 1-10 water doubly, 80 degrees centigrade to 100 degrees centigrade of boiling points, suction high speed centrifuge 15 minutes, automatically after isolating medicinal residues, medicinal liquid suction spraying drying tower is namely got the powdered thing, pack with thin aluminum bag.
3, medicine is synthetic: pour Caulis et folium clerodendri bungei extracted dry powder 25%-30% and Folium Perillae extracted dry powder 70%-75% into sealed blender stirring 15 minutes; sterilization; pack with capsule or tablet and can become medicine finished product (every 0.25 of capsule gram, every 0.5 gram of tablet) also to can be made into granule or teabag.
Medicine of the present invention has following advantage: mainly prepare burden Caulis et folium clerodendri bungei and Folium Perillae are easily purchased, and production technology is simple, and be inexpensive, easy to use, and prostate and infection diseases of urinary system are had immediate effect.
The using method of medicine of the present invention and Therapeutic Characteristics
1, every 0.25 of capsule of the present invention gram, oral three times of every day, each serving with four, 7 is a course for the treatment of, can thoroughly cure prostate and urinary system infection inflammation disease.
2, every 0.5 in tablet of the present invention gram, oral three times of every day, each serving with two, 7 is a course for the treatment of.
3, hematoma, edema are eliminated in contained multiple antitumor in the medicine of the present invention (swell and ache, enlargement) and cancer effective ingredient deep and thorough fast antiinflammatory in prostate body of gland and the urinary system tissue, detumescence, blood stasis dispelling under the forceful action of alkaloid parasite killing, sterilization.7 is a course for the treatment of.
4, medicine of the present invention is repaired rapidly the male because of mycoplasma and chlamydia that gonorrhea, the repeated infection of sexually transmitted disease (STD) intersection destroy, makes the loose shape of prostate body of gland (hypertrophy), and antiinflammatory is recovered to is with in normal body of gland week, makes urinary tract unobstructed.7 is a course for the treatment of.
5, the contained alkaloid rapid pin of medicine of the present invention has immediate effect to digestion and urination system normalization to prostate and urinary system infection antiinflammatory, sterilization, parasite killing (infusorian).7 is a course for the treatment of.
6, medicine of the present invention is being taken the infected inflammation of reparation system in medicine 2-4 of the present invention days to the inflammation of male prostate (hypertrophy) hypertrophy and urinary system infection initiation, prostatitis yellow or white liquid are no longer secreted or secreted less to genitals, and 7 is a course for the treatment of.
7, frequent micturition, urgent micturition, urine retention, dysurea, sexual anhedonia, painful ejaculation, anus twinge no longer occured in 2-4 days to the inflammation of male prostate and man, muliebria urinary system infection in medicine of the present invention after taking.
8, medicine of the present invention leucorrhoea grow in quantity, secretions stink or abnormal flavour that the women is caused because of gonorrhea, sexually transmitted disease (STD) repeated infection and metritis, pelvic inflammatory disease, cervicitis, uterine erosion, the twinge of sexual intercourse intravaginal pain, anus twinge, doing well,improving after taking medicine 2-4 of the present invention days can be cured after 7 days 21 times.
9, very serious women vaginitis, metritis, pelvic inflammatory disease, cervicitis, uterine erosion patient can be no less than 1 gram capsule or tablet with medicine of the present invention to put into the intravaginal effect better simultaneously taking medicine of the present invention every day, and 7 is a course for the treatment of.
Medicine important component raw material pharmacology research data of the present invention
1, contained chemical constituent in the Caulis et folium clerodendri bungei: colourless wax, referring in the S01 book the 112nd page, the chemical compound code name: 1168, have quick antiinflammatory, detumescence, expelling wind and activating blood circulation blood stasis dispelling function;
2, contained clerodendrin, clerodendron trichotomum element A, B, acacetin-7 glucosulfone aldehydic acid glycosides, despinning Inositol in the Caulis et folium clerodendri bungei, referring in the 634th page-635 pages of the third editions in the S02 book, the S03 book the 264th page, the blood pressure lowering of pharmacology tool, calmness, analgesia, wind-damp dispelling, pain relieving, hypertension, rheumatic arthralgia, have blood in stool, the usefulness such as urinary obstruction, fast antiinflammatory, detumescence, the various herpes of mouth bleb for the treatment of skin ulcer, sterilization;
3, contained chemical compound composition in the Folium Perillae: lauro lene, referring in the S01 book the 123rd page, the chemical compound code name: 1295, pharmacology has the usefulness such as resisting hypertension, hyperlipidemia;
4, contained chemical compound composition: β-Flos Caryophylli alkene is natural perfume material in the Folium Perillae, referring in the S01 book the 134th page, and the chemical compound code name: 1415, pharmacology has inhibitor effectiveness;
5, contained chemical compound composition in the Folium Perillae: linalool, referring in the S01 book the 536th page, the chemical compound code name: 5728, that pharmacology has is antibiotic, antifungal, antiviral, calmness, the usefulness such as anticorrosion;
6, contained chemical compound composition in the Folium Perillae: 1.2-methylene-dioxy-4-methoxyl group-5-pi-allyl-benzene-3-piece-β-D-pyranglucoside, referring in the S04 book the 115th, 116 page, the effects such as that pharmacology has is anticancer, antifertility, antiinflammatory, antiviral, blood sugar lowering, blood fat reducing and immunomodulating have obvious physiologically active to cardiovascular system, nervous system, interrenal system and enzymatic activity;
7, contained chemical compound composition in the Folium Perillae: the Folium Perillae olefine aldehydr, referring in the S01 book the 710th page, the chemical compound code name: 7722, have the effects such as sweeting agent;
8, contained chemical compound composition in the Folium Perillae: cupreol, referring in the S01 book the 824th page, chemical compound code name: 8903; Pharmacology has antitumor, pulmonary carcinoma and adenocarcinoma, the cough that antiinflammatory, ammonia cause, the usefulness such as resisting hypertension;
9, contained other effective ingredient in the Folium Perillae: referring to 755-757 page or leaf in the S05 book, have that treatment trusted subordinate distension, expelling pathogenic factors from muscles are delivered, acute mastitis swells and ache, the therapeutic method to keep the adverse QI flowing downwards, except excessive cold invading middle-JIAO(the spleen and stomach), except plug heat, control all cold air, invigorating the spleen and replenishing QI, end cramp caused by acute vomiting and diarrhea, whetting the appetite, relieving bowels, logical heart channel, strengthening the spleen stomach, dispersing wind and cold, promoting the circulation of QI to alleviate the stagnation in middle-JIAO, the sharp lung of expectorant and blood warming middle-JIAO to relieve pain, Dingchuan are antiabortive, solving toxin of fish and crab, kill in all ichthyosacrotoxins, the dream usefulness such as consumption of essence;
10, also contain volatile oil in the Folium Perillae in the chemical constituent, main component is in the oil: perillaldehyde, perilla alcohol, limonene, linalool, Mentholum, Flos Caryophylli alkene also contain elsholtziakesone, perilla ketone, eugenol and alkaloid 20%, referring to the 639th page of the third edition in the S02 book, have the heating that general heating, typhoid fever mixing are caused and have obvious curative effects
11, contain 20% alkaloid in the Folium Perillae, alkaloid is the azacyclo-structure that is present in many tools of class complexity of biosphere, and have alkalescence and a general name that contains organic compound of notable biological activity, most of alkaloids can be combined with acid salify, has complicated circulus, nitrogen-atoms is included in the ring, has optical activity and special and significant biological agent.
12, alkaloidal alkalescence is because contain one or more nitrogen-atoms in their chemical constitution, nitrogen-atoms in the alkaloid is the same with nitrogen-atoms in the amine, a pair of lone pair electron pair is arranged, proton there is certain captivation, so be alkalescence, can be combined into the antibacterial and sterilizing function of salt formation with acid.
13, alkaloidal biological activity is mainly reflected in: the activity of cardiovascular system aspect, and anti-tumor activity, parasite killing and Antiparasitic Activity, antibiotic, antiviral activity, to the activity of digestion Excretory system, active to neural effect and solution spasm.Referring in the S04 book the 116th, 254,272,273,280,281,282, page or leaf.
Scientific research proves: entered since the eighties in 20th century, the research of U.S. scientific circles is found, the a-linolenic acid of Perilla plant species in oils and fats has the important activity effect to function of nervous system, and finds that further this fatty acid has the effect that suppresses cancer and improve allergic constitution.National Cancer Institute in May nineteen ninety (NCD) is focused on research and development utilization with the Folium Perillae herb as anti-cancer food in the health food project.
In the various constant nutritional labelings of Folium Perillae blade, crude protein content is up to 28%, and the aminoacid kind reaches 18 kinds, belongs to complete protein.
The vitamin of Folium Perillae blade, mineral element contain the micro-mineral element of multiple needed by human body, and these elements all play an important role at balance the body environment, support and the aspects such as participation human body chemical reaction, regulate body temperature and structure sclerous tissues.Wherein beta-carotene has important physiology and pharmacological function, and it can stimulating immune system, improves body immunity, suppresses cancer etc.
The a-linolenic acid has antithrombotic and blood pressure lowering, keeps that brain and function of nervous system are normal in the contained volatile oil of Folium Perillae, prevention canceration and inhibition tumor cell shift, suppress the effects such as metamorphosis, property disease.
Referring in the S06 book the 431st, 432,440 page
Preparation of the present invention (capsule or tablet) is carried out relevant toxicity, pharmacology and clinical research, and the result shows:
One, acute toxicity test
Adopt preparation of the present invention (capsule or tablet) to Kunming kind mice lavage administration maximum tolerated dose greater than 16g/kg, for 167 times of human body clinical application amount (clinical one-tenth body weight for humans 50kg meter, 4.8g/ day, 0.096g/kg), so clinical drug safety.
Two, long term toxicity test
Adopt preparation of the present invention (capsule or tablet) gastric infusion two groups of Kunming kind rat dosage on the 1st to be respectively 4g/kg, 1.5g/kg be equivalent to 42 times and 15.6 times of adult (50g/kg) day oral dose (0.096g/kg), experiment periods is to observe after 2 weeks of drug withdrawal 35 days (4 courses for the treatment of that are equivalent to clinical application), each treated animal general status of medication is good, the body weight sustainable growth, the animal hair color is normal, hemogram, blood parameters, organ coefficient, pathologic finding and matched group be no significant difference relatively, thereby point out medicine of the present invention (capsule or tablet) that the long term toxicity effect is not appearred in Kunming kind rat, also have no the Delayed onset toxic action.
Three, preclinical pharmacology research
The function of preparation according to the present invention, carried out respectively the test of pesticide effectiveness of the aspects such as antiinflammatory, antibiotic, diuresis, analgesia, the result shows that this product has obvious antibacterium bactericidal action, diuresis, analgesic activity, and ACH can be resisted and BACL2 causes smooth muscle spasm, obviously suppress Kunming mouse abdominal cavity capillary permeability increasing action due to the glacial acetic acid, obviously improve the phagocytic function of Turnover of Mouse Peritoneal Macrophages.
Four, preparation of the present invention is to the clinical trial for the treatment of trimester of pregnancy Chronic Urinary Tract Infection
Pharmacological evaluation proof preparation of the present invention has obvious inhibition and killing action to escherichia coli, Fructus Vitis viniferae bacillus, Bacillus proteus, gonococcus, and the functions such as the immunity of enhancing, diuresis are arranged.In order further to estimate this medicine to the efficacy and saferry of pregnancy women Chronic Urinary Tract Infection, the People's Hospital, Yingde City, Guangdong Province divides secondary that urology department, OPD of Obs ﹠ Gyn are treated and observed, for the first time by treatment trimester of pregnancy 30 Cases of Urinary Tract Infection, preferably effect has been received in treatment, by observing and treatment urogenital infections patient 105 examples, also received preferably effect for the second time.
For the first time clinical data and method:
(1) physical data
In August, 2006-JIUYUE.Oldest 43 years old, minimum 22 years old, mean age, about 27.63; The longest 40 weeks in pregnant week, the shortest 6 weeks, average 32.87 weeks.
(2) diagnostic criteria, Excluded cases
1, diagnostic criteria
(1) Western medicine diagnose is gonorrhea, sexually transmitted disease (STD) and Chronic Urinary Tract Infection person, has the performance of following symptom and lab testing
The A pregnancy women;
B urinary tract irritation: frequent micturition, urgent micturition, dysurea;
The C midstream urine is conventional: leukocyte is greater than more than 3-5;
The D Urine culture: negative bacillus greater than more than 100,000/milliliter thalline, positive coccus is greater than 10,000/milliliter thalline.
(2) differential diagnosis in tcm is stranguria, lower warmer wetness-heat type:
Frequent micturition, urgent micturition, dysurea, urine yellow skin are red, red tongue, yellow and greasy fur, wiry and frequent pulse or sliding number.
2, Excluded cases
(1) gets rid of the diseases of urinary system such as acute urinary tract infection, lithangiuria, acute and chronic nephritis.
(2) the serious primary disease person such as cardiovascular, Liver and kidney and hemopoietic system is arranged.
(3) do not take medicine in accordance with regulations or the full person of data.
(3) observation index
1, observes treatment front and back frequent micturition, dysurea, urgent micturition, lumbago shape.
2, laboratory observation index (respectively doing routine urinalysis or CCMS before and after the treatment cultivates).
3, observation has no adverse reaction, such as rubella, the tired disease of digestion and general reaction.
(4) administrated method
Capsule of the present invention or tablet, oral, one day three times, 2 in 4 of each capsules or tablet.
(5) clinical efficacy
Organize the clinical observation on the therapeutic effect result of 30 routine pregnancy with combination of urinary tract infection from this, clinic control 20 examples account for 66.66%, and produce effects 6 examples account for 20%, and effective 2 examples account for 6.67%, and total effective rate is 93.33%.Symptom improves significantly to frequent micturition, dysurea, urgent micturition, the urine yellow skin of urinary tract infection be red etc.Untoward reaction does not occur during clinical practice, without genotoxicity.
For the second time clinical data and method:
This group is observed urogenital infections patient 105 examples altogether, acute urinary tract infection 55 examples wherein, Chronic Urinary Tract Infection acute attack 40 examples, chronic prostatitis acute attack 10 examples.Among the 105 routine patients, male's 37 examples, women's 68 examples, age 17-88 year, average 46.8 years old, course of disease 1-30 days, average 4.9 days (chronic case is calculated with the acute attack stage course of disease)
One, Western medicine diagnose: acute urinary tract infection or Chronic Urinary Tract Infection acute attack person or chronic prostatitis acute attack person have following symptom and lab testing:
1, urinary tract irritation frequent micturition, urgent micturition, dysurea.
2 or the red or urethral orifice adularescent secretions of companion urine yellow skin, lumbago, lower abdomen pain, dizziness, fever with aversion to cold etc.
3, routine urinalysis sediment microscopic inspection, leukocyte are greater than 10/HP, or a small amount of albumen, erythrocyte.
4 Urine cultures, the bacteria quantified breeding bacteria is greater than 10 five powers/ML.
5, prostatic fluid microscopy, leukocyte is greater than 10/HP.
6, prostatic fluid bacteria quantified breeding bacteria is greater than 10 five powers/ML.
(2) differential diagnosis in tcm is the stranguria lower warmer wetness-heat type: unexpected urine urgency-frequency, and the urethra scorching hot twinge, the red or companion's lumbago of urine yellow skin, urethra drips white, lower abdomen stomachache, fever with aversion to cold, red tongue, yellow and greasy fur, and wiry and frequent pulse or sliding number.
(3) get rid of urethra symptom group, tuberculosis of urinary system, lithangiuria, the diseases of urinary system such as acute and chronic nephritis.
Two, observation index:
Clinicing symptom observation: it is red to observe frequent micturition before and after the treatment, urgent micturition, dysurea, urine yellow skin, lumbago, and lower abdomen pain, the symptoms such as heating are added up with integration.
Lab index is observed: observation treatment front and back routine urinalysis CCMS cultivation prostatic fluid microscopy or prostatic fluid increase foster, and statistics is analyzed with Ridie.
Observation has no adverse reaction, such as erythra, symptom of digestive tract etc.
Three, Therapeutic Method and the course for the treatment of:
Oral medicine of the present invention: 2 in four of each capsules or tablet, every day three times, seven days is a course for the treatment of, stop using during the treatment other heat and toxic materials clearing away medicine and antibiotic Chinese and western drugs.
Four, curative effect determinate standard:
In the recent period recovery from illness: the clinical symptoms complete obiteration, symptom average product score value is treated front decline 3/4 after the medication, and routine urinalysis or prostatic fluid microscopy are normal, and midstream urine or prostatic fluid are negative.
Produce effects: clinical symptoms disappears substantially, and to treat front decline 1/2, routine urinalysis or prostatic fluid microscopy normal for symptom average product score value after the medication, and midstream urine or prostatic fluid are negative.
Effectively: clinical symptom relief, symptom average product score value is treated front decline 1/3 after the medication, and routine urinalysis or prostatic fluid microscopy obviously improve, and midstream urine or prostatic fluid idol have the positive.
Invalid: clinical symptoms is without improvement, routine urinalysis, prostatic fluid microscopy, and Urine culture, prostatic fluid are without improvement.
Five, therapeutic outcome:
(1) symptom integral Change in Mean before and after the treatment
Symptom average product score value is 9.27 plus-minuss 3.60 before the treatment
Symptom average product score value is 3.16 plus-minuss 2.35 after the treatment
Symptom is significantly improved the P value less than 0.01 after the treatment
(2) the clinical symptoms integration changes before and after the treatment
| Clinical symptoms | Case load | Integration before the treatment | Integration after the treatment | Rate of descent |
| Heating | 20 | 30 | 3 | 90％ |
| Frequent micturition | 90 | 196 | 72 | 63.27％ |
| Urgent micturition | 90 | 181 | 54 | 70.17％ |
| Stranguria | 77 | 126 | 27 | 78.57％ |
| The urine yellow skin is red | 27 | 42 | 13 | 61.82％ |
| Lower abdomen pain | 57 | 85 | 24 | 71.76％ |
| Lumbago | 71 | 122 | 61 | 50％ |
| Amount to | 105 | 782 | 254 | 67.52％ |
Each symptom all is improved in varying degrees to generate heat after the treatment, dysurea, urgent micturition, frequent micturition, lower abdomen pain, urine yellow skin be red for more obvious.
(3) lab index efficacy analysis
1, lab index is remarkable with urine thin born of the same parents, erythrocytopenia after the treatment.
Change the P value before and after the treatment respectively less than 0.001, less than 0.05, significant difference is arranged.
2, front prostatic fluid microscopy leukocyte 10 examples for the treatment of are all positive, and rear 8 examples for the treatment of are normal, normalization rate is 80%.
3, before the treatment Urine culture 24 example positive, more than the equal 100,000/ML of colony counting.
22 examples turn negative after the treatment, and negative conversion rate reaches 91.67%
Urine culture is relatively before and after the treatment:
4, prostatic fluid 5 examples are positive, and 2 examples turn negative after the treatment
Prostatic fluid relatively before and after the treatment
(4) total effects analysis:
This organizes 105 routine total effective rates 91.43%
Attached bibliography:
S01: " the former plant chemical ingredient handbook of Chinese medicine, Chemical Industry Press's in JIUYUE, 2004 is published, the Zhou Jiaju chief editor.
S02: " Chinese herbal medicine color atlas ", the 3rd printing May in 2006 of Fujian science tech publishing house, Xu Guojun writes.
S03: " North Guangdong medical herbs book ", published in 1969 at Shaoguan, Guangdong Province prefecture revolutionary committee and sanitary work station, prefecture, Shaoguan.
S04: " plant chemical ingredient " Chemical Industry Press in JIUYUE, 2004 is published, the Chen Yegao chief editor.
S05: Compendium of Material Medica Nanjing version, the People's Health Publisher publishes in November, 1999.
S06: " plant resource explorations research and application ", the first impression in May, 2005 of publishing house of Southeast China University.
Claims (2)
1. quick-acting medicines for the treatment of prostate and urinary system infection, it is characterized in that: the water extract that Caulis et folium clerodendri bungei and Folium Perillae extract and contain the raw material components Caulis et folium clerodendri bungei extracted dry powder 25%-30% of following percentage by weight in the medicine made, Folium Perillae extracted dry powder 70%-75%, above raw material components percentage by weight sum is 100%
2. production technology for the treatment of the quick-acting medicines of prostate and urinary system infection, it is characterized in that: with the Caulis et folium clerodendri bungei clean it up, be ground into 80-120 order powder through pulverizer, heated 15-30 minute in the heating cylinder with powder weight 1-10 water doubly, 80 degrees centigrade to 100 degrees centigrade of boiling points, suction high speed centrifuge 15 minutes, automatically after isolating medicinal residues, medicinal liquid suction spraying drying tower is namely got the powdered thing, pack with thin aluminum bag, with the Folium Perillae clean it up, be ground into 80-120 order powder through pulverizer, heated 15-30 minute in the heating cylinder with powder weight 1-10 water doubly, 80 degrees centigrade to 100 degrees centigrade of boiling points, suction high speed centrifuge 15 minutes, automatically isolate medicinal residues after, medicinal liquid suction spraying drying tower is namely got the powdered thing, pack with thin aluminum bag, medicine is synthetic: pour Caulis et folium clerodendri bungei extracted dry powder 25%-30% and Folium Perillae extracted dry powder 70%-75% into sealed blender stirring 15 minutes, capsule or tablet or granulation are made in sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110132678 CN102198191B (en) | 2011-05-16 | 2011-05-16 | Quick acting medicine for treating prostate and urinary system infections, and production process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110132678 CN102198191B (en) | 2011-05-16 | 2011-05-16 | Quick acting medicine for treating prostate and urinary system infections, and production process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102198191A CN102198191A (en) | 2011-09-28 |
| CN102198191B true CN102198191B (en) | 2013-01-02 |
Family
ID=44659346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110132678 Expired - Fee Related CN102198191B (en) | 2011-05-16 | 2011-05-16 | Quick acting medicine for treating prostate and urinary system infections, and production process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102198191B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948683A (en) * | 2014-03-28 | 2014-07-30 | 卢美云 | Tofu residue-like leucorrhea gynecopathy treatment traditional Chinese medicine and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797214A (en) * | 2010-04-16 | 2010-08-11 | 祝根华 | Quick-acting toothpaste for preventing and curing mouth diseases and periodontitis and production process thereof |
-
2011
- 2011-05-16 CN CN 201110132678 patent/CN102198191B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797214A (en) * | 2010-04-16 | 2010-08-11 | 祝根华 | Quick-acting toothpaste for preventing and curing mouth diseases and periodontitis and production process thereof |
Non-Patent Citations (1)
| Title |
|---|
| 贾海瑞.食药兼用植物紫苏的应用研究与发展前景.《农技服务》.2007,第24卷(第2期),第102-104页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102198191A (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
| CN102145111B (en) | Traditional Chinese medicine composition for treating colpitis mycotica and preparation method thereof | |
| CN103800772A (en) | Gynecological external lotion for preventing and treating vagina inflammatory diseases and preparation method thereof | |
| CN103301408B (en) | Traditional Chinese medicine extract and massage cream prepared from extract | |
| CN105213941A (en) | A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof | |
| CN103536826B (en) | One is treated colpitic Chinese medicine composition and preparation method thereof | |
| CN101288754B (en) | Huyuebao preparation | |
| CN103908611A (en) | Traditional Chinese medicine preparation for treating colon cancer and preparation method of traditional Chinese medicine preparation | |
| CN101391065B (en) | Compound momordica seed pepper soup for treating urgent chronic pelvic inflammatory disease | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN103041247A (en) | Traditional Chinese medicine suppository for curing colpitis and preparation method thereof | |
| CN102139051A (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN102872300B (en) | Traditional Chinese medicine for treating non-gonococcal urethritis | |
| CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
| CN102198191B (en) | Quick acting medicine for treating prostate and urinary system infections, and production process thereof | |
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN102526620A (en) | Traditional Chinese medicinal composition for treating gynecological inflammation and application of same | |
| CN105031487A (en) | Traditional Chinese medicine composition for treating children's jaundice caused by retention of dampness in the spleen and stomach | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN104288518A (en) | Traditional Chinese medicine composition for treating cervicitis | |
| CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
| CN103599190A (en) | Traditional Chinese medicine composition for treating light-headedness | |
| CN104068283B (en) | For preventing and treating the feed of sheep pox, Chinese medicine composition, preparation method and application | |
| CN110463799A (en) | A kind of wild plant composition of protect liver constipation-relieving tea | |
| CN103599253B (en) | Traditional Chinese medicine composition for treating winter pruritus of old people |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130102 Termination date: 20150516 |
|
| EXPY | Termination of patent right or utility model |